Core Insights - ARS Pharmaceuticals reported a total revenue of $84.3 million for the full year 2025, with $72.2 million coming from neffy sales in the U.S. [6][31] - The company has a strong balance sheet with $245.0 million in cash and short-term investments, which is expected to support operations through anticipated cash-flow break-even [6][31]. - The commercial launch of neffy, an epinephrine nasal spray, is progressing well, with a focus on expanding market share and securing unrestricted access with major payors [3][8]. Financial Performance - Fourth quarter revenue was $28.1 million, including $20.3 million from neffy sales, $6.9 million from collaboration revenue, and $0.9 million from supply revenue [6][31]. - R&D expenses for 2025 totaled $13.2 million, while SG&A expenses reached $230.1 million, reflecting significant investment in marketing and commercialization efforts [6][31]. - The net loss for the full year 2025 was $171.3 million, or $1.74 per share [6][31]. Commercial Launch and Market Strategy - The company is focusing on renewing initial prescriptions in 2026 as neffy reaches expiration, which is expected to accelerate market share expansion [2]. - ARS Pharma is expanding its sales force from 106 to 150 to increase prescribing depth among healthcare providers [8]. - The "Get neffy on Us" campaign aims to facilitate patient transitions to neffy, contributing to a growing base of new patients likely to renew prescriptions [8]. Regulatory and Clinical Developments - neffy has received regulatory approvals in multiple regions, including China and Australia, with additional approvals anticipated in Canada [8][18]. - A Phase 2b trial for the intranasal epinephrine program is ongoing, with interim data expected in mid-2026 [10]. Market Access and Payor Engagement - Progress with insurers has been positive, with eight state Medicaid plans covering neffy without prior authorization [8]. - The company targets a gross-to-net retention of approximately 50% while maximizing unrestricted payor access to drive volume [8].